文献速递眼底病与葡萄膜炎

AZGP1通过阻断PI3K/AKT信号通路减轻视网膜下纤维化并抑制上皮-间质转化

AZGP1 Attenuates Subretinal Fibrosis and Inhibits Epithelial-Mesenchymal Transition by Blocking the PI3K/AKT Signaling Pathway.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

研究在C57BL/6J小鼠中用两阶段激光诱导建立视网膜下纤维化(SRF)模型,通过RNA-seq发现AZGP1是显著下调基因之一。玻璃体腔注射重组AZGP1可减少RPE/脉络膜铺片中的胶原I和CD31阳性面积,并在ARPE-19细胞中抑制TGFβ1诱导的上皮-间质转化(EMT)。作者认为外源性补充AZGP1可能通过PI3K/AKT通路抑制RPE的EMT来改善SRF。

要点

  • 两阶段激光诱导的C57BL/6J小鼠SRF模型中,Azgp1是显著下调基因之一。
  • 玻璃体腔注射rAZGP1可减少RPE/脉络膜铺片中胶原I和CD31阳性面积。
  • rAZGP1可降低TGFβ1诱导后ARPE-19细胞的胶原I、α-SMA和纤连蛋白表达。

核心结论

  • AZGP1的异常表达模式对SRF的发生至关重要。
  • 外源性补充AZGP1可能通过PI3K/AKT通路抑制RPE内的EMT,从而成为改善SRF的潜在策略。

研究设计与样本

  • 采用两阶段激光诱导方案在C57BL/6J小鼠中建立SRF模型。
  • 对第二次激光后10天和30天的样本行RNA-seq以鉴定差异表达基因(DEGs),并用定量RT-PCR验证包括AZGP1在内的所选DEGs表达水平。
  • 玻璃体腔给予重组AZGP1(rAZGP1)以观察其对SRF的影响,并用ARPE-19细胞展示AZGP1在调控EMT中的作用。

主要发现

  • RPE/脉络膜复合体RNA-seq在第二次激光后10天与30天样本间共鉴定出66个DEGs(log2(fold change) ≥ 1,错误发现率[FDR] < 0.05),Azgp1是最显著下调基因之一。
  • 玻璃体腔注射rAZGP1明显减少RPE/脉络膜铺片中的胶原I和CD31阳性面积。
  • 在nAMD患者(GSE135922)和SRF小鼠模型中观察到AZGP1与RPE65共定位。
  • rAZGP1处理使TGFβ1诱导后ARPE-19细胞中胶原I、α-SMA和纤连蛋白表达显著降低。
  • 敲低和过表达研究均表明AZGP1调控ARPE-19细胞内的PI3K/AKT信号通路。

关键数值与推荐

  • DEGs筛选标准为log2(fold change) ≥ 1且FDR < 0.05,第二次激光后10天与30天样本间共66个DEGs。

临床怎么用

  • 作者认为外源性补充AZGP1可能通过抑制RPE内EMT的PI3K/AKT通路成为改善SRF的潜在策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Subretinal fibrosis (SRF) represents a significant contributor to irreversible vision loss in patients with neovascular age-related macular degeneration (nAMD). This study aimed to elucidate the underlying mechanism of SRF and identify potential therapeutic targets. METHODS: The SRF model was established using a two-stage laser-induced protocol in C57BL/6J mice. RNA-seq analysis was conducted to identify differentially expressed genes (DEGs) at 10 days and 30 days post-second laser. Quantitative RT-PCR was used to validate the expression levels of selected DEGs including zinc-alpha-2-glycoprotein 1 (AZGP1). Recombinant AZGP1 (rAZGP1) was intravitreally administrated to investigate its effects on SRF. The ARPE-19 cells were used to demonstrate the role of AZGP1 in modulating epithelial-mesenchymal transition (EMT). RESULTS: RNA-seq of RPE/choroid complex identified a total of 66 DEGs between samples collected at 10 days and 30 days post-second laser compared with controls (log2(fold change) ≥ 1, false discovery rate [FDR] < 0.05), with Azgp1 being one of the most significant downregulated genes. Intravitreal injection of rAZGP1 markedly reduced collagen I and CD31 positive areas in RPE/choroid flat-mounts. Co-localization of AZGP1 and RPE65 was observed in patients with nAMD (GSE135922) and SRF mouse models. Treatment with rAZGP1 resulted in significantly lower expressions of collagen I, α-SMA, and fibronectin in ARPE-19 cells after TGFβ1 induction. Both knockdown and overexpression studies demonstrated that AZGP1 regulated the PI3K/AKT signaling pathway within ARPE-19 cells. CONCLUSIONS: The abnormal expression pattern of AZGP1 is critical for the development of SRF. Exogenous supplementation with AZGP1 may represent a promising strategy for ameliorating SRF by inhibiting EMT within RPE through the PI3K/AKT pathway.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Yang Y, Shen J, Li Y, et al. AZGP1 Attenuates Subretinal Fibrosis and Inhibits Epithelial-Mesenchymal Transition by Blocking the PI3K/AKT Signaling Pathway. Invest Ophthalmol Vis Sci. 2025. PMID: 40305469. doi:10.1167/iovs.66.4.83

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。